Opinion

Justin J. Friedly: I believe there is still a tremendous opportunity to seek and lead the convergence of diagnostics, therapeutics, and data

Photo taken from Justin J. Friedly/LinkedIn

Oct 15, 2023, 16:06

Justin J. Friedly: I believe there is still a tremendous opportunity to seek and lead the convergence of diagnostics, therapeutics, and data

Justin J. Friedly, Former Vice President of National Accounts at Caris Life Sciences, shared on LinkedIn:

“Over the last 18+ years of my career, I have witnessed a radical transformation in oncology diagnostics. The early years included the automation of immunohistochemistry, which is now the standard of practice in anatomic pathology labs. (Thank you, Dr. Grogan) Healthcare has now begun the transition to the power of genomics and the market is tasked to drive testing closer to the patient to improve care and outcomes. While this progress has had huge impacts on the lives of those afflicted with cancer – I believe there is still a tremendous opportunity to seek and lead the convergence of diagnostics, therapeutics, and data.

I am thrilled with the number of organizational executive leaders that have reached out to me over the last week to discuss how this can be achieved. Compartmentalization of efforts by discipline over the last decade has throttled the potential of these synergies. Organizations that seek to embrace a variety of professional experiences, knowledge, and relationships will truly drive the frontier of cancer care globally. The harmonization of diagnostics, therapeutics, data, and AI within the walls of a single organization will break every paradigm that currently exists.

I am excited to find my new ‘family’ that embraces this concept and culture, not out of fear or necessity, but out of what is ultimately best for the patient and the future of cancer care in the U.S. and Global Markets.

Hoping to be blessed with a new journey and opportunity soon…”

Source: Justin J. Friedly/LinkedIn